Telomeres, stem cells, senescence, and cancer by Sharpless, Norman E. & DePinho, Ronald A.
160 The Journal of Clinical Investigation | January 2004 | Volume 113 | Number 2
Every day, we sacrifice many varied cell types such as
granulocytes, keratinocytes, hepatocytes, and erythro-
cytes at the altar of organismal homeostasis. For the
individual to thrive, lost cells must be constantly
replaced, and recent evidence has identified significant
capacities for repair and regeneration even in organs
once thought to be postmitotic such as the pancreatic
islet and the brain. Given this continuous cellular attri-
tion, normal tissue function requires that the rate of
cell loss be matched by the rate of renewal. Aging is has-
tened by forces that either accelerate cellular loss or
retard tissue repair. When loss exceeds repair, ensuing
cellular attrition eventually leads to a decline in organ
function and ultimately failure. When restricted to spe-
cific organs, this condition would be expected to result
in one of the many chronic degenerative diseases such
as liver cirrhosis. If, however, the process operates
across multiple organ systems, then this progressive
multisystem functional compromise may manifest
clinically as frailty, accelerated aging, and death.
Elegant experiments from lower metazoans with
postmitotic soma (e.g., Drosophila and Caenorhabditis ele-
gans) have identified many of the pathways that influ-
ence the rate of cellular turnover and loss (reviewed in
refs. 1, 2). These data have firmly established a link
between the rate of cellular metabolism, the rate of pro-
duction of unstable oxygen species, and longevity in
these species. There appears little doubt that many of
these conserved pathways (e.g., insulin-like growth fac-
tor-1 signaling) also influence the rate of mammalian
metabolism and cellular decay, and therefore mam-
malian aging. As extensive tissue replacement does not
occur in adults of these lower organisms, however,
these model systems have been less helpful with regard
to the genes that regulate tissue repair in the adult and
thereby influence this aspect of aging. Therefore, one
advantage of mammalian genetic systems is that they
permit the investigation of the pathways responsible
for the repair half of the aging equation.
To be sure, adult mammals require extensive prolif-
eration and tissue replacement to survive. Even in the
absence of pathology, the intestinal lining replaces
itself entirely on a weekly basis, and the bone marrow
produces trillions of new blood cells daily. An obvious
cost of this massive and obligate proliferation, howev-
er, is that even under physiological conditions, it is pre-
sumed that stem cell genomes are showered with
somatic mutations, some of which may target cancer-
relevant genes. In accord with this view is the remark-
able observation that roughly 1% of neonatal cord
blood collections contain significant numbers of
myeloid clones harboring oncogenic fusions such as
the AML-ETO fusion associated with acute leukemia
(3); similarly, as many as one in three adults possess
detectable IgH-BCL2 translocations, which are com-
monly associated with follicular lymphoma (4). As the
prevalence of these cancers is far lower in the general
population, it would appear that potent tumor sup-
pressor mechanisms function to monitor and con-
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strain the growth and survival of these aspiring cancer
cells. In humans, three principal and overlapping
tumor suppressor barriers appear to be operative; they
are represented by the p16INK4a–retinoblastoma protein
(p16INK4a-Rb) pathway, the ARF–p53 pathway, and
telomeres. The combined effect of these tumor sup-
pressor mechanisms is to place a limit on the replica-
tive life span of cells in the compartment capable of
contributing to tissue regeneration (hence termed stem
cells). In this Perspective, we will discuss these tumor
suppressor mechanisms and the hypothesis that their
anticancer roles come at the cost of a decline in stem
cell number and their proliferative reserve, thereby
compromising tissue repair and promoting the aging
phenotype. We will detail the human and murine data
in support of this hypothesis, and discuss the implica-
tions of the intimate link between cancer and aging.
Tumor suppressor pathways engender 
senescence and apoptosis
A common endpoint for these major tumor suppres-
sor mechanisms is senescence. This specialized form of
terminal differentiation is induced by a variety of stim-
uli including alterations of telomere length and struc-
ture, some forms of DNA damage (for example, oxida-
tive stress), and activation of certain oncogenes
(reviewed in refs. 5, 6). Senescence requires activation
of the Rb and/or p53 protein, and expression of their
regulators such as p16INK4a, p21, and ARF (7–10) (Fig-
ure 1). An important form of senescence is induced by
p53, which has several antiproliferative activities
including stimulation of the expression of p21, a
cyclin-dependent kinase inhibitor (CDKI). CDKIs
inhibit progression through the cell cycle by inhibit-
ing cyclin-dependent kinases that phosphorylate and
thereby inactivate Rb and related proteins p107 and
p130 (11). The activity of p53 is predominantly medi-
ated by inhibiting its murine double minute 2 protein
(MDM2)–mediated degradation, and p53 is stabilized
by diverse stimuli including DNA damage signals (e.g.,
resulting from oxidative stress or telomeric shorten-
ing) and oncogene activation (reviewed in refs. 12–14).
The stabilization of p53 by oncogenes is in part medi-
ated by ARF (also designated p19ARF in the mouse),
which is induced by inappropriate cell cycle entry
(15–17), and binds to MDM2, thereby inhibiting the
destruction of p53 (15, 18–20). Another CDKI,
p16INK4a increases markedly in senescent cells, and cor-
relates with increasing Rb hypophosphorylation dur-
ing this process (8, 9). The regulation of p16INK4a in
senescence is not as well understood as that of p53,
although it appears to be induced by several stimuli
including MAP kinase signaling, oncogene activation,
and growth in culture (21–24). Either p53-p21 or
p16INK4a are able to produce Rb hypophosphorylation
and initiate senescence. Some senescence-inducing
stimuli (e.g., activation of the RAS oncogene) appear
to induce both pathways, while others (e.g., DNA dam-
age) appear to preferentially activate one or the other.
Senescence differs from other physiologic forms of
cell cycle arrest such as quiescence in two important
ways (Table 1). First, senescence in somatic cells is gen-
erally irreversible, barring the inactivation of p53
and/or Rb, which appear to be required for its mainte-
nance in certain settings (10, 25–27). Second, it is asso-
ciated with distinctive molecular and morphologic
alterations such as cellular flattening and increased
adherence, a loss of c-fos induction to serum stimula-
tion, an increased expression of plasminogen activator
inhibitor (PAI) and the expression of senescence-asso-
ciated β-galactosidase activity (reviewed in refs. 6, 28).
Recently, senescence has been shown to correlate with
the establishment of an unusual form of heterochro-
matin present in discrete nuclear foci, known as senes-
cence-associated heterochromatic foci (SAHF) (29). In
aggregate, these data suggest that senescence results
from the durable repression of promoters associated
with growth control genes. This repression is enforced
by the construction of stable, heterochromatin-like
complexes, the formation of which is directed in part
by hypophosphorylated Rb.
Recent evidence suggests senescence may differ qual-
itatively depending on the stimulus that leads to its
establishment. Several groups have shown that either
Rb or p53 inactivation could reverse the senescence in





Induced by: Telomere shortening Serum starvation
Prolonged DNA damage Growth factor deprivation
Oxidative stress Growth at high density
Oncogene (e.g., RAS) activation Transient DNA damage
SA β-gal expression Present Absent
SA heterochromatic foci Present Absent
Molecular markers Uninducible c-fos expression to serum stimulation Inducible c-fos expression to serum stimulation
Increased PAI expression Low PAI expression
Cell cycle inhibitors p16INK4a, ARF, p53, p21, Rb p53, p21, p27, Rb
AIn the setting of sustained p53 and/or Rb function (see text for details). SA, senescence-associated; SA β-gal, senescence-associated β-galactosidase.
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(10, 26, 27). Therefore, it seems clear that persistent
p53 and Rb function are required to maintain certain
forms of senescence. Campisi and colleagues, however,
have reported that certain human cell types senesced in
a p16INK4a-dependent manner, while in other cells
senescence was p53-mediated (25). Intriguingly, while
the authors could revert p53-mediated senescence
using lentiviral vectors expressing SV40 Large T Anti-
gen (which inactivates Rb and p53), p16INK4a-mediated
senescence was durable and not reversible by T Antigen.
Of note, the formation of SAHF was more marked in
p16INK4a -mediated senescence, suggesting the possi-
bility that Rb and p53 are no longer required after the
establishment of these repressive chromatin structures
(29). As both p16INK4a and p21 induce Rb hypophos-
phorylation, however, the molecular basis for the dif-
ference between these forms of senescence is unclear.
Therefore, robust and validated senescence markers are
needed to dissect these issues.
In addition to senescence, it is worth noting that can-
cer-related stimuli such as oncogene activation, DNA
damage, and telomere shortening can also induce an
entirely distinct anticancer mechanism, namely apop-
tosis. Apoptotic loss of progenitor cells in response to
such stimuli has been clearly demonstrated in animal
models; for example, mice with shortened, dysfunc-
tional telomeres demonstrate increased apoptosis in
germ cells of the testes and crypt cells of the intestine
(30–32). In these systems, an increase in apoptosis cor-
relates with tissue atrophy and other phenotypes asso-
ciated with premature aging. The role of p53 in medi-
ating apoptosis is well-documented (33, 34), and this
activity seems its major anticancer function in certain
animal models (35, 36). Correspondingly, p53 loss
greatly attenuates the apoptotic phenotype seen in pro-
liferative organs in the setting of telomere dysfunction
in animal models (37). While loss of p53 in these ani-
mals affords resistance to the effects of telomere dys-
function, these mice also demonstrate a marked
increase in epithelial tumor formation (37, 38), rein-
forcing the view that aging and cancer are closely linked
in this model system. Therefore, telomere shortening
and p53 activation modulate two potent anticancer
mechanisms: senescence and apoptosis. While the
molecular biology of this fate-decision is incompletely
understood, the specific response appears to depend on
many variables including cell type, genetic context, and
proliferation state. Although a role for p16INK4a in
inducing apoptosis has been suggested (39–42), the
issue of whether p16INK4a also has senescence-inde-
pendent anticancer functions in vivo remains an area
of active investigation.
Telomeres, telomerase, and checkpoints
Telomeres are nucleoprotein complexes at the chro-
mosome ends which consist of many double-stranded
TTAGGG repeats, a 3′ single strand overhang, and
associated telomere binding proteins (Figure 2)
(reviewed in refs. 43, 44). It has been known since the
early days of maize genetics that telomeres play a criti-
cal role in the maintenance of chromosomal integrity
— a fact that has since been confirmed in diverse model
systems from yeast to plants to humans. Interestingly,
however, telomere lengths differ greatly, even among
mammals. For example, human telomeres are 5 to 15
kb long while those of inbred mice may exceed 60 kb.
Several lines of evidence have established that telom-
eres adopt a complex secondary and tertiary structure
that relies on DNA-DNA, DNA-protein, and protein-
protein interactions. With regard to senescence, telom-
ere structure appears at least as important to telomere
function as absolute telomere length (45–47).
DNA polymerase cannot fully replicate the ends of
linear DNA duplexes, and, in the absence of telomerase,
chromosomes shorten slightly with every cell division.
Telomerase is a specialized RNA-protein complex that
is responsible for the de novo synthesis and mainte-
nance of telomere repeats. The telomerase holoenzyme
consists of a telomerase RNA component (TERC) that
serves as a template for the addition of repeats, and a
protein component, telomerase reverse transcriptase
(TERT). Telomerase expression is low or absent in most
human somatic tissues, with its expression principally
restricted in the adult to activated lymphocytes, germ
cells, and tissue stem cells (48–51). The restricted pat-
tern of telomerase activity relates primarily to the strict
regulation of TERT gene transcription, whereas TERC
gene expression is broader in distribution. The most
widely accepted model holds that progressive telomere
shortening with each cell division eventually triggers an
alteration in telomere structure. From the perspective
Figure 1 
The p53 and Rb pathways. p53 activity is predominantly regulated
at the protein level. In the unstressed state, p53 is rapidly degraded
by MDM2; a process which is inhibited by ARF. Also, p53 can be sta-
bilized by N-terminal serine phosphorylation in response to genotoxic
stresses, and this phosphorylation inhibits its interaction with
MDM2. p53 activation potently induces either growth arrest or
apoptosis depending on cellular context. The antiproliferative activ-
ity of p53 in part results from p21 expression, which is a p53 tran-
scriptional target. Rb is inactivated by phosphorylation as a result of
the cyclin-dependent kinases CDK4 and CDK6. Hypophosphorylat-
ed Rb binds E2F and represses proliferation. CDK activity is inhibit-
ed by both p16INK4a and p21.
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of senescence and apoptosis, the most important result
of this telomere dysfunction is that the deprotected
telomere end becomes, for all intents, a double-strand
break (DSB) of DNA. Classical DSBs potently induce
p53, and telomere dysfunction in cultured human and
mouse cells has been shown to induce p53-mediated
senescence or other checkpoint responses depending
on the cell type.
The relationship between telomere dysfunction and
activation of the p16INK4a-Rb pathway is less clear. For
example, TERT expression in cultured human fibro-
blasts abrogates progressive p16INK4a accumulation and
the onset of senescence (52), a result that has generally
been interpreted to suggest that dysfunctional telom-
eres produce a signal that activates p16INK4a. Alterna-
tively, it is possible that TERT per se possesses func-
tions, independent of its telomere lengthening effects,
capable of quelling p16INK4a activation. The expression
of a dominant negative form of telomeric repeat bind-
ing factor 2 (TRF2), a telomere binding protein, will
induce an acute alteration in telomere structure accom-
panied by growth arrest in human and murine cells
(45). In human cells, senescence can be induced by a
dominant negative TRF2 (DN-TRF2) through either
p16INK4a- or p53-dependent mechanisms, while, in
murine cells, p53 loss alone is sufficient to abrogate
growth arrest by DN-TRF2 (53). Likewise, loss of
p16INK4a and ARF does not rescue the gonadal failure
and other in vivo apoptotic responses seen in mice har-
boring telomere dysfunction (54). On the other hand,
the placement of human epithelial cells and murine
cells in culture has been shown to rapidly induce
p16INK4a in the absence of telomere shortening (16,
55–57). Therefore, like p53, p16INK4a appears to be
induced by telomere-dependent and -independent
stimuli. The accumulation of p16INK4a in many tissues
is noted with aging in both mice and humans (24, 58),
but whether this results from in vivo alterations of
telomere structure remains to be established. Similar-
ly, it is unclear if the major in vivo tumor suppressor
function of p16INK4a in humans results as a response to
telomere dysfunction or other stimuli.
In the absence of the p53– and p16INK4a-Rb–mediat-
ed checkpoints, cultured cells with dysfunctional
telomeres continue to proliferate, entering a period of
slow growth called “crisis” that is characterized by
genomic instability. Clones emerging from crisis
invariably either reactivate telomerase (59–61) or the
alternative lengthening of telomeres (ALT) mechanism
(62, 63). During crisis, the deprotected telomere ends
in proliferating cells can be illegitimately fused
through DNA repair mechanisms, ultimately leading
to the generation of complex non-reciprocal translo-
cations, a hallmark feature of adult solid tumors. In a
tissue stem cell, telomere dysfunction would appear to
have two outcomes depending on the integrity of
checkpoint mechanisms: respond to checkpoint acti-
vation with senescence/apoptosis or proliferate and
engender genomic instability. Evidence suggests that
most cells facing this decision respond to checkpoints,
producing a progressive diminution of stem cell
reserve throughout the human lifespan. This decline
in tissue regeneration capacity eventually manifests as
aging. The rare cells that continue to proliferate in the
setting of telomere dysfunction and emerge from cri-
sis having accumulated additional, transforming
mutations are equally problematic from the organis-
mal perspective. These cells necessarily have incurred
proliferative genetic lesions and inactivated tumor
suppressor checkpoints, and appear well on their way
down the path to full-fledged cancer.
Telomere-mediated checkpoints prevent 
cancer but contribute to aging
The vast majority of cells exhibiting telomere dysfunc-
tion undergo senescence or apoptosis, and disparate
lines of evidence have convincingly shown that these
processes are significant barriers to cancer formation.
Reactivation of telomerase is one of the most com-
monly observed features of cancer seen in greater than
80% of all human tumors (64–66). Telomerase expres-
sion greatly enhances the transformation of human
cells in vitro (67), and tumorigenesis is inhibited by
telomere shortening in animal models of cancer (54,
68, 69). In aggregate, these data suggest that telomere-
induced checkpoint activation is a major in vivo tumor
suppressor mechanism.
The tumor-promoting effects of telomerase activity
appear to be more complex than initially believed. Cer-
tainly, tumor clones must resolve the telomere length
problem to traverse crisis, and therefore telomerase reac-
tivation or the development of ALT is a prerequisite of
malignant growth. For this reason, inhibitors of telom-
erase have been considered promising therapeutic can-
didates for novel antineoplastic agents (70). Several lines
of evidence, however, also suggest that telomerase activ-
ity may contribute to tumorigenesis in a manner inde-
Figure 2
Telomere structure. Telomeres are present at chromosome ends. They
consist of linear arrays of repeat sequences that are 5–15 kb in humans
but considerably larger in mice. Telomeres also harbor a G-rich 3′ over-
hang that is important for the adoption of proper secondary structure.
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pendent of its telomere lengthening effects. For exam-
ple, telomerase expression has been shown, independ-
ent of telomere length, to produce resistance to the
antiproliferative signals of TGF-β in cultured mamma-
ry cells lacking p16INK4a (71). Additionally, animals over-
expressing telomerase are more prone to neoplasia than
littermate wild-type animals (72, 73), even though
telomere length per se does not appear to limit tumor
growth in these models. Lastly, transformed ALT+
murine clones demonstrate further enhanced growth in
a mouse model of metastasis after transduction with
telomerase (74). These disparate lines of evidence sug-
gest that the catalytic activity of telomerase contributes
to malignant growth by influencing a cellular feature in
addition to absolute telomere length, but the precise
mechanism of these effects has remained elusive. One
possibility has been suggested by the observation that
telomerase activity appears to affect the length of the
telomere 3′ overhang (Figure 2), which plays a role in
assumption of proper telomere structure, thereby mod-
ulating growth arrest or apoptosis independent of
absolute telomere length (46, 47).
In addition to preventing cancer, however, telomere-
mediated checkpoints appear to contribute to aging,
and, as stated, mice with shortened, dysfunctional
telomeres exhibit many characteristics of premature
aging (31). A consideration of ataxia telangectasia (AT)
is particularly intriguing in this regard. Humans with
deficiency of the AT tumor suppressor (ATM) (ataxia-
telangiectasia mutated kinase), which plays a role in
DNA damage signaling, develop a progeroid syndrome
in the setting of premature telomere shortening (75,
76). In comparison to humans, however, mice lacking
ATM harbor a more modest phenotype in terms of
aging. Such animals are markedly susceptible to
thymic lymphoma (77–80), consistent with a role of
ATM in sensing failed VDJ recombination intermedi-
ates (81). Strikingly, however, mice lacking ATM in the
setting of telomere shortening developed accelerated
aging and recapitulate more faithfully many features
of the human ATM deficiency (30). Furthermore,
Atm–/– mice with short telomeres developed less thymic
lymphoma despite increased mortality to non-cancer
causes. Although human AT patients are tumor prone,
these mice are presumably resistant to cancer because
they possess an otherwise intact p53 checkpoint, and
are not able to reactivate telomerase because of its
germline inactivation. Therefore, many of the age-
associated phenotypes seen in AT patients appear to
result from telomere dysfunction, which in turn
reflects premature telomere shortening. The mecha-
nism that produces premature telomere attrition in
AT patients, however, remains unclear.
Further direct genetic evidence for a role of telomere
dysfunction in human aging comes from the recent
discovery that germline mutations of the telomerase
complex cause the progeroid syndrome dyskeratosis
congenita (82). Also, telomere shortening has been
shown to precede the development of overt cirrhosis in
patients with chronic hepatitis of various etiologies
(83–86). In addition, several studies have demonstrat-
ed a relationship between telomere length in peripher-
al blood leukocytes (PBL) and the onset of certain 
diseases associated with aging. Such studies in non-
neoplastic diseases have shown that PBL telomere
lengths can provide predictive information on the risk
of developing atherosclerosis (87, 88) and on overall
mortality (89). In aggregate, these data indicate that
although telomerase plays a clear role in malignant
progression, telomere-induced checkpoints also con-
tribute to certain aspects of human aging.
Telomere dysfunction contributes to cancer
As telomere-mediated checkpoints are no doubt major
barriers to malignant progression in most would-be can-
cer cells, it therefore appears somewhat paradoxical that
telomere dysfunction may also fuel tumorigenesis.
Nonetheless, recent cytogenetic and molecular studies
have provided strong evidence that telomere dynamics can
contribute to genomic instability, particularly early in
tumorigenesis. In this model, a transient period of telo-
mere dysfunction contributes to carcinogenesis by engen-
dering large numbers of genome-wide changes (reviewed
in refs. 43, 90) (Figure 3). This occurs through breakage-
fusion-bridge cycles that result from the formation of
dicentric chromosomes after inappropriate fusions of
deprotected telomeres. This rapid reshuffling of the genet-
ic deck produces rare cells with a threshold number of rel-
evant changes to become full-fledged cancer.
Strong evidence that telomere-associated events are
indeed relevant to carcinogenesis derives from the
analysis of mice compound deficient for TERC and p53
(37, 38). In this system, p53 deficient mice with telom-
ere dysfunction demonstrate a marked shift in the
tumor spectrum towards epithelial cancers. Addition-
ally, these cancers exhibit the complex cytogenetic pro-
files found in human epithelial cancers as opposed to
the more bland cytogenetic profiles of spontaneous
Figure 3
Bridge-fusion-breakage. Under normal circumstances, the chromo-
some ends are protected by telomeres. When normal cells develop
telomere shortening, they undergo growth arrest or apoptosis in a p53-
or p16INK4a-dependent manner. In cells with checkpoint inactivation,
however, fusion between telomere-free ends leads to the formation of
dicentric chromosomes, which are then broken during anaphase.
These breakages produce non-reciprocal translocations and broken
chromosome ends that are substrates for further fusion events.
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kidney, bladder, and lung (104). While these correlative
results can be interpreted in several ways (105), sub-
stantiation of the utility of PBL telomere lengths as a
reliable surrogate marker for neoplasia would prove
invaluable in assessing patient risk of later developing
an epithelial malignancy.
It should be noted, however, that certain cancers, par-
ticularly those malignancies with simple cytogenetics
such as pediatric acute leukemia, occur without going
through an obligate period of genomic instability
induced by telomere dysfunction. Such tumors likely
accomplish this by solving the telomere-lengthening
problem prior to the onset of telomere dysfunction. Per-
haps these malignancies target a telomerase-expressing
compartment like the hematopoietic stem cell (HSC),
or involve potent activation of oncogenes like myc that
induce telomerase expression (106, 107). It is likely,
however, that these tumors represent a special, good-
prognosis case of cancer as they may neither require nor
possess the large number of genomic changes seen in
adult solid tumors resulting from telomere dysfunc-
tion. It is tempting to speculate that the improved prog-
nosis and response to therapy of hematopoietic com-
pared with epithelial cancers could relate to the fact that
solid tumors experience a DNA damage phase as part of
their life history. This phase may result in the obligate
deactivation of DNA damage checkpoints in order to
permit cancer cell survival, yet at the same time position
these cancers for resistance to a large class of DNA dam-
age–inducing cancer therapies.
How are cancer and aging linked in vivo?
The aforementioned data suggest that senescence is
induced in cultured cells by a variety of telomere-
dependent and telomere-independent mechanisms.
Likewise, the in vivo effects of inactivation (for p53 see
ref. 108, for p16INK4a see refs. 109, 110, and for telom-
erase see refs. 21, 32, 111) and hyperfunction (for p53
see refs. 112, 113, and for telomerase see refs. 72, 73)
have been determined in mice, confirming the hypothe-
ses that these mechanisms link cancer and aging. A
problem, however, from the use of germline knockout
animals and broadly expressing transgenics strains is
that it is not necessarily straightforward to determine
which effects are cell-autonomous and which are not
(Figure 4). For example, lymphocytes from adult
p16INK4a-deficient mice demonstrate an enhanced
mitogenic response to CD3 and CD28 (109), and loss
of this response is a hallmark feature of immunose-
nescence in mice (114). Problematically, however, the
expression of p16INK4a in lymphocytes is low relative to
other adult tissues (N.E. Sharpless, unpublished obser-
vation). Therefore, this resistance to aging seen in the
immune system of p16INK4a null mice could represent a
direct antiproliferative effect of p16INK4a on aged 
T-cells, or more likely could result from a role for
p16INK4a in other cell types, such as an antigen-present-
ing compartment. Therefore, a future challenge will be
to analyze animals with conditional inactivation of
mouse cancers (38, 91). While most cancers of adult
humans are epithelial in origin, spontaneous carcino-
mas are unusual in mouse tumor models. Therefore,
these data suggest that telomere dysfunction is an
important event in carcinoma formation, and telomere
dynamics play a major role in the species difference in
carcinoma frequency between humans and mice.
This model of telomere dysfunction–driven carcino-
genesis matches with the timing of telomerase activa-
tion and appearance of genomic changes during vari-
ous stages of epithelial tumorigenesis. For example,
comparative genome hybridization (CGH) has demon-
strated that early breast (92–94) and esophageal (95,
96) lesions sustain widespread gains and losses of
regions of chromosomes early in their development —
such ploidy changes detected by CGH correlate tightly
with the presence of complex chromosomal rearrange-
ments. This genomic instability phase is evident in
stages of high-grade dysplasia, and can be found before
the acquisition of a frankly malignant phenotype.
Correspondingly, the measurement of telomerase
activity in corresponding preneoplastic lesions has
demonstrated a consistent pattern with the ploidy and
cytogenetic changes (97–103). For example, studies of
adenomatous polyps and colorectal cancers have estab-
lished that telomerase activity is low or undetectable in
small- and intermediate-sized polyps with marked
increase in telomerase activity in large adenomas and
colorectal carcinomas. These data suggest that there is
widespread chromosomal instability early in neoplas-
tic progression at a time when telomerase activity is
low. As these cancers progress and reactivate telomerase
or ALT, genomic instability continues at a moderate
rate, with further mutations presumably resulting
from non–telomere-based mechanisms. Additionally,
it has recently been shown that the presence of short
telomeres in PBLs is associated with increased risk for
the development of carcinomas of the head and neck,
Figure 4
Cell-autonomous vs. non–cell-autonomous aging. Two models for
impaired tissue repair are suggested: target cells of aging are shown
in gray and senescent cell are shown in blue. In the cell-autonomous
case, senescence (or apoptosis) of a progenitor with self-renewal
capacity leads to impaired tissue regeneration in old animals. In the
non–cell-autonomous case, however, a support cell supplies a factor
(X), which is critical for the maintenance of tissue repair. X could be
a hormone (e.g., estrogen) acting at a distance or cell-cell interac-
tions (e.g., costimulatory signals from antigen-presenting cells) act-
ing in a paracrine manner. In this model, aging results from the func-
tional loss (e.g., by senescence) of the support cell, which may not
be detectable in the tissue of interest.
 
166 The Journal of Clinical Investigation | January 2004 | Volume 113 | Number 2
these pathways in order to resolve the complex effects
of their loss on organismal fitness and aging.
An additional conceptual problem stems from the
observation that the expression of p53 and telomere
shortening do not strictly correlate with the onset of
tissue aging (115–117). While undoubtedly telomere
shortening is seen in certain progeroid syndromes
and in states characterized by chronic hyperprolifera-
tion such as cirrhosis and myelodysplasia, it also
appears that telomere length is heterogeneous in the
human population, and shorter lengths do not always
correlate with aging. A caveat to this conclusion, how-
ever, is that these studies necessarily have analyzed
mean telomere length, although it appears that check-
point activation may occur in response to the short-
est telomeres in the cell (118). Nonetheless, while
telomere shortening can be seen immediately preced-
ing organ failure in states of high cellular turnover, it
may not be an obligate feature of all normal physio-
logic aging. This finding points to the existence of
telomere-independent causes of aging, as is almost
certainly the case in normal mice.
There are two important caveats to this sort of analy-
sis. First, only surviving cells are considered in these
molecular characterizations of aged tissues. Therefore,
one would not expect to detect telomere shortening
and p53 expression in cell types where these stimuli are
proapoptotic. Nonetheless, apoptotic loss of stem cells
may play an important role in organismal aging. Addi-
tionally, it is possible that alterations in telomere struc-
ture, which can potently induce senescence and apop-
tosis (45–47), occur in vivo. Therefore, alterations in
telomere dynamics may contribute to a decline in tis-
sue function even in the absence of an overall decrease
in telomere length.
Alternatively, p53 or p16INK4a activation may be con-
tributing to aging in a very restricted compartment
such as tissue stem cells. In this model, expression of
p16INK4a or p53 need not be detected throughout the
tissue to exert its senescence-related effects. There are
data from genetic systems in support of this view. For
example, loss of bmi-1, a repressor of p16INK4a and
p19ARF, leads to a decrease in HSC number (119), and
HSCs from Ink4a/Arf-deficient animals demonstrate
enhanced long-term function (120). These data col-
lectively suggest that one or both products of the
Ink4a/Arf locus, both potent inducers of senescence,
play a role in determining the long-term replicative
potential of murine HSCs. Similarly, the effects of
telomere shortening in mice are most immediately
obvious in the spermatagonia and colonic crypts (32),
which harbor the stem cells that give rise to the large
bowel mucosa. Mice with critical telomere shortening
demonstrate marked anaphase bridging and apopto-
sis in these progenitor-enriched compartments. There-
fore, the effects of these tumor suppressor pathways
may be disproportionately felt in the stem cell com-
partment, which represents a rare minority of cells in
any given tissue.
Summary
Given the aging populations in western nations, the
presently enormous problems of aging and cancer are
poised to become even greater public health and socioe-
conomic challenges (121, 122). A recent study of Amer-
icans receiving Medicare support estimated the entire
future lifetime health-related costs of the average
healthy 70-year-old to be approximately $150,000 per
individual (122), and the aggregate cost of this health
burden will only grow larger as increasing numbers of
Americans age and retire. A ray of hope from this analy-
sis, however, was suggested by the observation that the
healthiest 70-year-olds with the longest life expectancy
still had the lowest future health costs. Therefore, if a
goal of modern medicine is to extend patient survival,
then the future solvency of Medicare appears to hinge
on our ability not merely to extend overall survival, but
to extend disease-free survival (123).
Our new molecular understanding of cancer and
aging is a major tool in this effort, for two reasons.
First, we are beginning to develop molecular surrogate
markers of aging and future cancer risk. Such markers
will revolutionize medical advice regarding nutrition
and wellness. Amazingly, physicians have very little
hard evidence to support a given dose of vitamin sup-
plements, exercise, or diet; and most wellness thera-
peutics of proven benefit are directed toward a meas-
urable predisease state like hypercholesterolemia or
hypertension. By examining markers such as telomere
function or p53 / p16INK4a expression in a given tissue,
however, we may be able to better predict the future
onset of cancer and/or aging, and likewise determine
the beneficial or harmful effects of a therapeutic inter-
vention with regard to these surrogate endpoints.
Secondly, we will be able to improve our understand-
ing of environmental or lifestyle exposures that cause
or contribute to aging. Likewise, we will be able to iden-
tify which tissue compartments are targeted by these
exposures, allowing a delineation of the cell-autono-
mous and non–cell-autonomous effects. Whether such
an understanding of the environmental triggers of
aging will allow us to boost the maximum human lifes-
pan is highly controversial, but certainly at the mini-
mum such information would help extend the healthy
life expectancy; free of cancer and other adverse conse-
quences of aging.
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